GENUINE: Investigation of Ublituximab, a Novel CD20 Inhibitor, in Combination With Ibrutinib in Pts With Previously Treated High-Risk CLL

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
The addition of ublituximab to ibrutinib improved ORR vs ibrutinib alone with a similar safety profile except for an increase in ublituximab-related infusion reactions.
Format: Microsoft PowerPoint (.ppt)
File Size: 746 KB
Released: June 6, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings